Health
The Bigger Point Beyond Insilico's Aging Research Milestone
This week Insilico Medicine , an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a conventional disease…
- Published
- (2026-10-12)
- Outlet
- BioPharmTrend
- Section
- Health
- Length here
- Headline and 33-word snippet. The full article is at the source.
More from BioPharmTrend and around the same time
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying CustomersAnthropic filed for its IPO with the SEC on Monday, and its S-1 shows that 9 of the 10 largest pharmaceutical companies in the Fortune 500 each spent at least $100,000 with the company in the twelve months to September 30. Eight…Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflowsWith Science Foundries, launched today, the R&;D software company moves from helping scientists with individual tasks to managing entire scientific processes with teams of AI agents. The launch builds on a series of products…Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science on specific R&;D workflows…Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in LineRecently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after one of its weakest years in recent memory.Into the Dark: Finding Novel Drug Targets Within the Depths of Our ProteomeDrug discovery has never had a richer therapeutic toolbox. Antibody-drug conjugates, antisense oligonucleotides, CRISPR therapeutics, RNA medicines, CAR-T cells, PROTACs, and molecular glues have transformed how medicine can…The $2.7B Question: How Do We Know If Isomorphic's AI Works?Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a drug candidate.This page holds the headline and a short snippet as published by BioPharmTrend, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
